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ARTICLE
The effect of adalimumab on the vasculature in psoriatic skin lesions
S. C. A. Hanssen, C. J. M. van der Vleuten, P. E. J. van Erp, M. M. B. Seyger and P. C. M. van de Kerkhof
Department of dermatology, Radboud University Medical Centre, Nijmegen, GA, the Netherlands
ABSTRACT
Background: Vascular proliferation is considered an important feature in psoriasis. Early psoriatic changes
are characterized by vascular network expansion; healing of the lesions ultimately results in a decreasing
size of the vascular network. Currently, the response of the vasculature in psoriatic lesions during treat-
ment of adalimumab is still obscure.
Objective: To investigate the response of the vasculature in psoriatic lesions during adalimumab treat-
ment, using parameters such as endothelial cell proliferation, vascular network size and alternations in
vessel diameter.
Methods: The endothelial cell response (endothelial cell proliferation rate, vascular network size and ves-
sel diameter) was studied, using an immunohistochemical double-staining of Ki67/CD31, in subsequent
biopsies of psoriatic lesions from 10 patients treated with adalimumab at baseline, 10days and 16weeks
after initiation of treatment.
Results: In active psoriatic skin the endothelial cell proliferation ratio is high and an increased vascular
network size and vessel diameter is found. An evident decrease in all these parameters is found during
16weeks treatment with adalimumab. Keratinocyte proliferation already decreased significantly and sub-
stantially after 10 days treatment.
Discussion: Adalimumab treatment of psoriasis causes an evident reduction in endothelial cell prolifer-
ation, vascular network size and vessel diameter, parallel to the clinical improvement. Vascular parameters
do not capture early improvement to adalimumab treatment, however (non-)invasive measurement of
vascular function parallels, the clinical improvement and may be a valuable marker for disease activity.
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Psoriasis, a chronic inflammatory skin disease, is characterized by
raised, sharply demarcated, erythematosquamous plaques ranging
from a few millimeters to several centimeters in diameter.
Histological features of psoriasis include epidermal hyperplasia,
impaired epidermal differentiation, accumulation of inflammatory
cells and excessive angiogenesis with enlarged, tortuous and
hyperpermeable dermal blood vessels (1).
In psoriatic plaque development, one of the earliest events is a
vascular network expansion, which particularly occurs in the papil-
lary part of the dermis and appears to take place early, before
epidermal changes and persists after epithelial and inflammatory
alternations (2). In addition to an expanded vasculature, an
increased blood perfusion is observed in psoriatic lesions (3).
Vascular network expansion occurs by the process of neovascu-
larization, new blood vessel development, by two mechanisms:
angiogenesis and vasculogenesis. Angiogenesis occurs when endo-
thelial cells (ECs) sprout from preexisting blood vessels, migrate,
and proliferate to form new blood vessels. Vasculogenesis is de
novo formation of new vessels from the differentiation of endothe-
lial progenitor cells.
Neovascularization plays a crucial role in psoriasis; the exact
triggers that initiate the capillary morphological remodeling and
the timeframe in which they occur in psoriasis development are
still indistinct. This is an important niche in our understanding of
the pathogenesis of psoriasis because vascular remodeling and
its timeframe may be of major significance to the genesis and
maintenance of psoriatic lesions. More insight on this matter
could increase the possibility of related targets for therapy. In
addition, more knowledge about the role and reaction of the
vasculature might be relevant in an early assessment of therapy
effectiveness; perhaps using noninvasive methods like cutaneous
Doppler ultrasound.
In psoriatic skin, pro-angiogenic mediators, such as vascular
endothelial growth factor (VEGF), tumor necrosis factor-a (TNF-a)
and hypoxia inducible factor (HIF) are increased (4–8). TNF-a, a
naturally occurring cytokine, performs a crucial role in various
physiological processes including the immune defense and regu-
lation of vascular properties. TNF-a stimulates angiogenesis and
increases vessel permeability (9–14). Numerous clinical trials dem-
onstrated an impressive clinical efficacy (15–18) of TNF-a inhibi-
tors in the treatment of psoriasis.
Adalimumab, a TNF-a inhibitor, often prescribed in psoriasis, is a
recombinant human Immunoglobulin (IgG) monoclonal antibody.
Adalimumab binds soluble TNF-a with high affinity and specificity,
resulting in neutralization of the biological function of this cytokine
by blocking its interaction with the cell surface TNF-a-receptors.
Adalimumab modulates biological processes induced or regu-
lated by TNF-a, including changes of expression of adhesion mol-
ecules. Adhesion molecules, proteins located on the cell surface,
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are involved in binding with other cells or with the extracellular
matrix. Adhesion molecules play a key role in the recruitment and
migration of immune cells such as leukocytes; it is presumed that
adhesion molecules also play a crucial role in the regulation of
neovascularization and formation of atherosclerosis (4). Various
authors investigated the mechanism of action of TNF-a inhibitors
in psoriatic patients, focusing on different features of the patho-
genesis of psoriasis, such as immune responses and keratinocyte
differentiation. Although, TNF-a also has effects on the endothe-
lium, these effects of anti-TNF-a treatment on the (micro) vascula-
ture in psoriasis have not been studied before.
The aim of this study was to investigate the endothelial
changes (vascular network size, vessel diameter and endothelial
cell proliferation rate) in psoriatic skin during a 16week treatment
with adalimumab. In this assessment, the vascular changes are
analyzed in different parts of the dermis; the papillary and reticu-
lar dermis. In this way, the impact of treatment can be assessed
in different regions of the (epidermal) psoriatic skin.
Methods
Subjects
Specimens of human psoriatic skin were obtained from a previous
study performed at our department (19). Biopsies were attained
from 10 psoriasis patients (five women and five men; age
42–73 years) with moderate-to-severe chronic plaque psoriasis
(PASI score 10 or a PASI score 8 in combination with a
Skindex total score 35) treated with adalimumab for 16weeks.
All experiments were approved by the local medical ethics com-
mittee prior to the study and were conducted according to
the principle of the Declaration of Helsinki and in accordance
with the Medical Research Involving Human Subjects Act (WMO).
In all patients a written informed consent was acquired
before inclusion.
Adalimumab treatment
Patients were treated with an initial dose of 80mg adalimumab
given subcutaneously, followed by 40mg adalimumab subcutane-
ously every other week starting 1week after the initial dose. At
the baseline visit, one representative psoriasis lesion was defined
as the ‘target lesion’. At baseline, after 10 days and 16weeks of
treatment, SUM scores (scoring the erythema, infiltration, and des-
quamation) were assessed from the target lesion and a 4mm
punch biopsy was taken from this lesion under local anesthesia.
Immunohistochemistry
The skin biopsies were formalin-fixed, embedded in paraffin and
sectioned at 4 lm; previous analysis revealed that 4 lm was the
most optimal slice thickness for both immuno histochemical
markers (CD31 and Ki67) used in this study (results of this previ-
ous analysis are not included in this paper).
The paraffin-embedded sections were dewaxed, rehydrated
and antigen retrieval for the Ki67/CD31 double staining was
attained using a tris-EDTA buffer (pH 9.0, 10min at 96 C). After
which these were incubated primarily with Ki67 (proliferation
marker) and visualization of the Ki67 antibody was achieved with
a peroxidase-based EnVision-kit (DAKO, Glostrup, Denmark) 3–30-
diaminobenzidine metal enhanced (Metal Enhanced DAB sub-
strate-kit, Thermo Scientific, US). Subsequently, the sections were
incubated with CD31 (endothelial cell marker) in 1% bovine serum
albumin, followed by the visualization of CD31 which was
achieved with BrightVision (BrightVision Poly-AP anti-Ms IgG
from ImmunoLogic, the Netherlands). All tissue samples were
counterstained with Mayer’s hematoxylin (Sigma-Aldrich).
Substitution with 1% PBS served as negative controls.
Quantification of cells and surface area
The immunohistochemical tissue samples were captured using
the Mirax Midi Scanner (3DHISTECH, Budapest, Hungary) and
scanned in batch mode with tissue finding and fully automated
focusing, using an 20 objective lens [Plan-Apochromat (Carl
Zeiss, Jenna, Germany), NA ¼0.8]. Tissue images were set to a
compression ratio of 80% and stored in jpg-compression based
format (3DHistech). The specimen level pixel size for this setup is
0.23 lm (20).
The open source imaging processing package Fiji 1.47 was
used for all image analyzes. The regions of interest of the dermal
compartment were divided in papillary dermis (PD) and de reticu-
lar dermis (RD). The PD is defined as the dermis area within the
papillae up to the base of the basement membrane. The RD can
be described as the surface from the basement down to 350 lm.
The vascular network size was examined using the vascular
area ratio (VAR) and the microvascular density (MVD). The VAR
represents the area occupied by (micro) vessels; CD31 positive
area in a selected area. The MVD refers to the number of vessels
in a selected area. The vessel diameter (VD) can be defined as the
smallest part of vessel-lumen (in mm) surrounded by CD31 stained
Endothelial cells (ECs).
Proliferating endothelial cells (pECs) can be described as ECs
that double stain the Ki67 (proliferation marker) and CD31 (endo-
thelial marker). The pECs were numerated and expressed as Ki67-
positive ECs relative to the total surface of the endothelium.
With respect to the epidermis an area was measured across
the whole section, without stratum corneum. Keratinocyte Ki67þ
nuclei were expressed as the sum of positive cells per millimeter
length of the basement membrane.
Statistics
Statistical analysis was performed using SPSS 20.0 statistical soft-
ware (SPSS, Chicago, USA). Data were expressed as mean± stan-
dard error of mean (SEM). Time-related changes were assessed
using a one-way ANOVA repeated measures test, followed by a
Bonferroni post hoc test. Throughout the analyzes, p values <.05
were considered statistically significant.
Results
Clinical results
At baseline, the mean PASI (Psoriasis Area and Severity Index) was
16.93 (SEM 2.64). Ten days after treatment initiation, a clinical
improvement in PASI score was seen in half of the patients.
During adalimumab therapy the PASI declined to 14.94 (SEM 2.63)
after 10 days and to 1.07 (SEM 0.42) after 16weeks. The mean
SUM score (score of erythema, infiltration and desquamation) of
the target lesion declined from 6.90 (SEM 0.35) at baseline to 6.00
(SEM 0.69) after 10 days an to 0.40 (SEM 0.27) after 16weeks (19).
Ki671 keratinocytes
At baseline, a number of 173.8 ± 4.8 Ki67þ keratinocytes per mm
basement membrane were demonstrated. An obvious decline was
already found after 10 days (119.7 ± 6.3; p< .05) and continued to
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decline 16weeks after starting treatment (41.9 ± 2.2; p< .05)
(Figures 1 and 2).
Proliferation of endothelial cells
At baseline, a number of 23.0 ± 5.7 Ki67þ nuclei in the ECs were
found in the total dermis; papillary dermis (PD)þ reticular dermis
(RD). A decrease in proliferating ECs (pECs) in the total dermis is
observed 10 days after adalimumab initiation, although this is
not significant (p¼ .28); after 16weeks of therapy the decline
becomes substantial (p< .01). The amount of pECs in the PD is
obviously higher than in the RD (Table 1).
Vascular network size
The size of the vascular bed was determined on the basis of 2
parameters, the VAR and the MVD. The VAR, the area fraction cov-
ered with vessels, in the total dermis (PDþ RD), was 9.1 ± 0.3% at
baseline. Only after 10 days, a clear decrease (7.2 ± 0.2%; p< .05)
was observed in the total dermis. This decline was even greater
at the final measurement, 16weeks after treatment was started
(4.6 ± 0.2%; p< .05).
The surface covered with vessels compared to the total tissue
area (VAR) in the PD is considerably higher than in the RD during
the entire experiment; the difference in VAR ratio’s among the PD
and RD is most pronounced at baseline (before treat-
ment initiation).
The VAR in the PD decreases considerably after the first
10 days of treatment, although this decrease is not yet significant
(13.3 ± 0.4 versus 12.9 ± 0.4; p¼ .12). The decrease is substantial
16weeks (8.7 ± 0.3%; p< .05) after starting the adalimu-
mab therapy.
The VAR of the RD shows a less marked decrease after 10 days
of treatment; it appears to remain more or less the same during
the first 10 days of treatment with a VAR of 5.9 ± 0.2%. Sixteen
weeks after treatment inception the VAR of the RD declines evi-
dently (4.1 ± 0.2%; p< .05).
The number of (micro) vessels per unit area (MVD) of psoriasis
skin (total dermis) was 71.6 ± 1.8mm2 at baseline. Sixteen weeks
after initiation of the adalimumab treatment, the MVD was obvi-
ously reduced (p< .05).
Vessel diameter (VD)
The mean vessel width of the vessels in involved psoriatic skin
was 13.7 ± 0.1lm before treatment. This value was significantly
reduced (12.8 ± 0.1lm; p< .05) after 10 days of treatment with
adalimumab and the decline endured during continuation of the
treatment; sixteen weeks after initiation of the Adalimumab treat-
ment the VD was 8.6 ± 0.1lm (p< .05).
Discussion
Psoriasis is characterized by a high ECs proliferation value, a
strong enlargement of vascular bed and aberrant tortuous dilated
capillary loops (1). This study revealed that adalimumab treatment
of psoriatic skin causes a considerable reduction in ECs prolifer-
ation, vascular bed size (vascular area ratio, (micro) vascular dens-
ity) and vessel diameter. Improvement of the (micro) vascular
changes was associated with an evident decrease in keratinocyte
proliferation and clinical improvement (SUM score 6.9 at baseline
vs. 0.4 after 16weeks) (19).
The vascular changes (ECs proliferation, expansion of the vas-
cular network size and increase in the vessel diameter) are most
pronounced in (the capillary loops in) the papillary dermis of
affected psoriatic skin (as opposed to the reticular dermis). This
observation was in agreement with previous studies that sug-
gested that EC proliferation appears to arise mostly in the papil-
lary dermis (21,22). This suggests that vascular expansion mainly
derives through proliferating ECs in the papillary dermis, and to a
lesser extent in deeper layers of the dermis. In the reticular der-
mis, some sporadic Ki67þ ECs were observed; in previous studies
no proliferating ECs were found in the reticular dermis (21,22).
The relatively modest clinical improvement of psoriasis in the
first 10 days after adalimumab therapy (a reduction of the average
PASI of 16.93 to 14.94) is reflected in the mild improvement of
the endothelium (the relatively small decline of the VD, vascular
network size and ECs proliferation value). On the contrary, adali-
mumab treatment is already accompanied by a significant
decrease in the keratinocyte proliferation during the first 10 days.
Alternations in the endothelial parameters (decrease in pECs, vas-
cular network size and VD) become distinct after 16weeks
of treatment.
Initially, the relatively mild reduction in vascular network size is
probably particularly caused by a declining vessel diameter (and
perhaps an associated decline ECs thickness), since the amount of
vessels (MVD) appears to remain quite stable during the first
10 days of treatment, while the VD already significantly decreases.
This assumption can be supported by Hendriks et al. who
observed a marked reduction in the perfusion intensity in psori-
atic lesions with obvious clinical improvement on therapy, while
the expression of dermal CD31þ remained obviously elevated
(23). Hern et al. found similar results using native capillaroscopy
Table 1. Characteristics of microvasculature in psoriatic plaque skin before and during Adalimumab treatment.
p-value
Pre-treatment (P1) 1.5 weeks treatment (P2) 16 weeks treatment (P3) P1 vs. P2 P1 vs. P3
Total Dermis
Microvessel density (mm–2) 71.6 ± 1.8 70.5 ± 1.6 64.5 ± 1.4 p¼ .98 p< .05
Vascular area ratio 0.09 ± 0.00 0.07 ± 0.00 0.05 ± 0.00 p< .05 p< .05
Vessel diameter (lm) 13.7 ± 0.1 12.8 ± 0.1 8.6 ± 0.1 p< .05 p< .05
Endothelial cell proliferation (Ki67þ nuclei/mm–2) 23.0 ± 5.7 11.7 ± 1.6 4.1 ± 2.1 p¼ .28 p< .05
Papillary Dermis
Vascular area ratio 0.13 ± 0.00 0.13 ± 0.00 0.09 ± 0.00 p¼ .92 p< .05
Endothelial cell proliferation (Ki67þ nuclei/mm–2) 131.9 ± 31.0 75.5 ± 14.4 30.9 ± 16.0 p¼ .30 p< .05
Reticular Dermis
Vascular area ratio 0.06 ± 0.00 0.06 ± 0.00 0.04 ± 0.00 P¼ .94 P< .05
Endothelial cell proliferation (Ki67þ nuclei/mm–2) 6.6 ± 3.4 1.9 ± 1.3 0 p¼ .85 p¼ .27
Results are presented as mean ± standard error of the mean (SEM); n¼ 10. (One-way ANOVA repeated measures test; Bonferroni post hoc test).
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images of plaque microvessels in psoriasis patients treated with a
pulsed dye laser (24).
In conformity with the decline in pECs, the size of the vascular
network (defined as VAR and MVD) decreases over time. It is
noted that ECs proliferation de facto represents angiogenesis and
that the values found in our experiment are directly connected to
vascular network size.
Adalimumab therapy blocks tumor necrosis factor-a (TNF-a), a
cytokine that directly stimulates keratinocyte proliferation as well
as angiogenesis and chemotaxis of inflammatory cells. In the con-
text of psoriatic lesion, the effects of adalimumab on the endo-
thelium proved to have a more backward role in the initial phase
of the disease, but the vascular parameters correlated well with
clinical improvement. In this study it could not be made clear
Figure 1. Overview of Immunohistological results. (a) Microvascular density (MVD): the number of (micro)vessels in a selected area (per mm2) of the total dermis,
(b) Vessel diameter (in mm) in the total dermis, (c) Ki67þ keratinocytes per mm length of basement membrane, (d) Endothelial Cell proliferation (Ki67þ EC nuclei/
CD31þ mm2) within a selected area of the total dermis, (e) Endothelial Cell proliferation (Ki67þ EC nuclei/CD31þ mm2) within a selected area of the papillary dermis,
(f) Endothelial Cell proliferation (Ki67þ EC nuclei/CD31þ mm2) within a selected area of the reticular dermis, (g) Vascular Area Ratio (VAR): fraction of the area occu-
pied by (micro)vessel within a selected area of the total dermis, (h) Vascular area ratio (VAR): fraction of the area occupied by (micro)vessels in a selected area of the
papillary dermis, (i) Vascular area ratio (VAR): fraction of the area occupied by (micro)vessels in a selected area of the reticular dermis. The Bar charts represent the
results of the analyzed items at baseline and 10 days (1.5 weeks) and 16weeks after the initiation of Adalimumab treatment. Means ± SEM. p< .05: statistically signifi-
cant compared to baseline; : statistically significant compared to 2 subsequent biopsies.
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whether vascular changes precede changes in keratino-
cyte-activity.
Results demonstrated that the VD is the first vascular param-
eter that revealed a significant decline; the VD is inextricably
linked to the cutaneous perfusion (25). Therefore monitoring of
the endothelium, using the noninvasive approaches (such as cuta-
neous Doppler ultrasound), may be a valuable (vascular) marker
to assess therapy efficacy and residual disease activity beyond the
naked eye.
Ki67/CD31 double-staining proved a straightforward approach
to quantify angiogenesis, also providing the opportunity to obtain
extra information on other vascular parameters, such as the
extent of the vasculature (MVD and VAR) and vessel diam-
eter (VD).
In summary, clinical improvement due to adalimumab in psor-
iasis during a 16-week study was accompanied by substantial vas-
cular changes in immunohistochemistry: a considerable reduction
in endothelial cell proliferation, vascular network size and vessel
diameter were observed. The Ki67/CD31 double-staining proved a
straightforward approach to quantify angiogenesis, also providing
the opportunity to obtain extra information on other vascular
parameters, such as the extent of the vasculature (MVD and VAR)
and vessel diameter (VD). Especially the endothelial cells in the
papillary dermis (as opposed to the reticular dermis) of active
psoriatic skin expressed proliferative activity, which was inhibited
relatively fast due to adalimumab. In this study it could not be
made clear whether vascular changes precede changes in kera-
tinocyte-activity.
The VD (which is inextricably linked to cutaneous perfusion) is
the first vascular parameter that declines after starting adalimu-
mab treatment. Monitoring of the cutaneous perfusion (VD), using
noninvasive approaches as Doppler ultrasound, may be a valuable
marker to assess therapy efficacy. Further studies are needed to
find out whether noninvasive skin imaging could contribute to
assessment of residual disease activity in psoriasis.
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